Route: GAVAGE

Test Type: 26-39 WEEKS

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 11:53:07 First Dose M/F: NA / 11/18/04

Date Report Requested: 07/22/2009

Lab: NCTR

C Number: C20310C

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

Lock Date: 12/01/2008

Cage Range: ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include 917 Vehicl PND1-8 F Include 918 AZT 40 PND1-8 F

**Study Gender:** Female

**TDMSE Version:** 2.1.0

Route: GAVAGE

Test Type: 26-39 WEEKS

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 11:53:07

Date Report Requested: 07/22/2009

First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Disposition Summary		
Animals Initially in Study Early Deaths	26	26
Survivors Moribund Sacrifice Natural Death	1	3
Terminal Sacrifice Animals Examined Microscopically	25 26	23 26
- Indiana - Indi		20
ALIMENTARY SYSTEM		
Intestine Large, Cecum Hyperplasia, Lymphoid	(25) 3 [2.0]	(26)
Liver Basophilic Focus	(25)	(26) 1
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	2 [1.0] 2 [1.0]	1 [1.0]
Tension Lipidosis Vacuolization Cytoplasmic	3 [1.3] 12 [1.0]	4 [1.5] 6 [1.0]
Salivary Glands Infiltration Cellular, Lymphocyte	(25) 15 [1.1]	(26) 12 [1.2]
CARDIOVASCULAR SYSTEM		
Heart Heart	(25)	(26)
ENDOCRINE SYSTEM		
Adrenal Cortex	(26)	(26)
Subcapsular, Hyperplasia Thyroid Gland	23 [1.2] (26)	24 [1.1] (26)
Degeneration Ectopic Thymus	2	1 [1.0] 1

#### **GENERAL BODY SYSTEM**

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 11:53:07

Date Report Requested: 07/22/2009

First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
None		
GENITAL SYSTEM		
Ovary Cyst Uterus Infiltration Cellular, Polymorphonuclear	(26) 4 [2.3] (26) 1 [2.0]	(26) 1 [2.0] (26)
Endometrium, Hyperplasia, Cystic Lumen, Dilatation	4 [1.5] 16 [1.5]	3 [1.7] 13 [1.2]
HEMATOPOIETIC SYSTEM		
Bone Marrow Lymph Node Renal, Hyperplasia, Lymphoid Lymph Node, Mandibular Hyperplasia, Lymphoid Lymph Node, Mesenteric Hyperplasia, Lymphoid Spleen Hematopoietic Cell Proliferation Hyperplasia, Lymphoid Thymus Cyst, Multiple Hyperplasia, Lymphoid	(25) (0) (25) (25) 4 [1.5] (26) 2 [3.0] 6 [2.3] (25) 1 [2.0]	(26) (2) 1 [1.0] (25) 1 [1.0] (26) 3 [1.0] (26) 2 [2.0] 6 [2.2] (25) 1 [4.0] 3 [1.3]
INTEGUMENTARY SYSTEM		
INTEGUMENTARY SYSTEM		(26)

#### **NERVOUS SYSTEM**

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:53:07 First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Brain, Brain Stem Brain, Cerebellum Brain, Cerebrum Mineralization	(26) (26) (26) 2 [1.0]	(26) (26) (26) 4 [1.0]
RESPIRATORY SYSTEM		
Lung Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	(26)	(26) 1 [2.0] 1 [1.0]
SPECIAL SENSES SYSTEM		
Harderian Gland	(25)	(26)
URINARY SYSTEM		
Kidney Infiltration Cellular, Lymphocyte Urinary Bladder Infiltration Cellular, Lymphocyte Lumen, Dilatation	(25) 9 [1.1] (25) 2 [1.0] 1 [4.0]	(26) 5 [1.0] (26) 3 [1.0]

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)